中型制药市场战略、顶级参与者、增长机会、2031 年分析和预测

  • Report Code : TIPRE00018321
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Mid sized pharmaceutical Market Scope (2021-2031)

Buy Now

中型制药市场规模预计将从 2023 年的 7,320.2 亿美元增至 2031 年的 12,240.39 亿美元。预计 2023-2031 年市场复合年增长率8.9%。更加注重研发可能仍然是市场的主要趋势。

中型制药市场分析

市场的增长是由关键驱动因素决定的,例如全球老年人口的增加以及慢性疾病患病率的增加。此外,城市化进程的加快增加了政府在医疗保健领域的支出。此外,医疗保健初创企业数量的增加可能会在未来几年为中型制药市场提供机会。

中型制药市场概览

人口老龄化和社会行为的变化导致这些常见且代价高昂的长期健康问题稳步增加。随着城市化进程的加快,人们越来越倾向于久坐的生活方式。这会增加肥胖率和糖尿病等疾病的发病率。据世界卫生组织预测,到 2026 年,慢性病患病率预计将增加 57%。新兴市场将受到最严重的打击,因为发展中国家的人口增长预计最为强劲。由于慢性病而对医疗保健系统的需求不断增加已成为一个重大问题。

糖尿病是21世纪最大的全球健康问题之一。每年,越来越多的人患上这种疾病,导致改变生活的并发症。根据国际糖尿病联盟 ( IDF ) 的数据,2019 年北美糖尿病患者人数约为 4600 万,预计到 2045 年将增加到 6200 万。在预测期间,疾病患病率增加约 35%。大流行病考验了全球感染的传播速度。流行病对健身系统产生周期性和巨大的破坏性压力。全球各地的医疗机构都希望做好准备,以在疫情集体爆发时遏制疫情。因此,慢性疾病患病率的增加推动了中型制药市场的发展。

定制研究以满足您的要求

我们可以优化和定制我们的标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

中型制药市场:

Mid-Size Pharmaceutical Market: Strategic Insights

Mid-Size Pharmaceutical Market
  • CAGR
    CAGR (2023 - 2031)
    8.9%
  • Market Size 2023
    US$ 732.02 Billion
  • Market Size 2031
    US$ 1,224.039 Billion

Key Players

  • DAIICHI SANKYO COMPANY LIMITED
  • Eisai Co Ltd
  • Regeneron Pharmaceuticals Inc
  • Bausch Health Companies Inc
  • Sun Pharmaceutical Industries Ltd
  • Alexion Pharmaceuticals Inc
  • Mallinckrodt
  • Endo Pharmaceuticals Inc
  • Les Laboratories Servier
  • UCB S A

Regional Overview

Regional And Country Scope
  • 北美(美国、加拿大、墨西哥)
  • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
  • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
  • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
  • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)

Market Segmentation

Segment 1类型(处方药、非处方药)
    Segment2药物开发类型(内部和外包)
      Segment3剂型(药片、胶囊、注射剂、喷雾剂、其他剂型)
        Segment4治疗课程(心血管疾病、疼痛管理、糖尿病、癌症、其他疾病)

          中型制药市场
          • Mid-Size Pharmaceutical Market
            年均复合增长率(2023 - 2031)
            8.9%
          • 2023年市场规模
            7320.2亿美元
          • 2031 年市场规模
            12,240.39 亿美元

          市场动态

          增长动力
          • 增加投资以提高药品制造能力,提振中型药品市场
          未来的趋势
          • 技术转让和外包趋势的采用为中型制药市场提供了重大的增长机会
          机会
          • 市场参与者积极参与产品创新和开发,推动中型制药市场的增长

          关键人物;主力;重要一员

          • 第一三共有限公司;
          • 卫材有限公司;
          • 再生元制药公司;
          • 博士健康公司;
          • 太阳制药工业有限公司;
          • 亚力兄制药公司;
          • 马林克罗特;
          • 远藤制药公司;
          • 施维雅实验室;
          • 联合银行有限公司

          区域概况

          Mid-Size Pharmaceutical Market
          • 北美
          • 欧洲
          • 亚太
          • 南美洲和中美洲
          • 中东和非洲

          市场细分

          Mid-Size Pharmaceutical Market类型
          • 处方
          • 在柜台
          Mid-Size Pharmaceutical Market药物开发类型
          • 内部和外包
          Mid-Size Pharmaceutical Market公式
          • 片剂和胶囊
          • 注射剂
          • 喷雾剂
          • 其他配方
          Mid-Size Pharmaceutical Market治疗班
          • 心血管疾病
          • 疼痛管理
          • 糖尿病
          • 癌症
          • 其他条件
          • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

          中型制药市场驱动因素和机遇

          增加产品批准和发布

          各种市场参与者的存在是中型制药市场的特征。为了增加市场份额,市场参与者采取各种策略,例如产品发布、区域扩张和技术进步。中型制药企业更多地参与持续创新和技术进步,从而提高行业参与者的接受度。领先企业投资研发以开发先进技术并获得更多收入。例如,2022年5月,卫材株式会社推出了MOVICOL HD,这是现有MOVICOL LD的先进配方,用于治疗慢性便秘。 EA Pharma 和卫材株式会社根据联合推广协议合作提供正确使用 MOVICOL HD 的信息。此外,2022 年 5 月,Sun Pharmaceutical Industries Ltd.(包括其子公司和联营公司)宣布,其仿制美沙拉嗪缓释胶囊 500 毫克的简略新药申请 (ANDA) 获得美国 FDA 的最终批准。仿制药批准以 Pentasa 缓释胶囊 500 毫克作为参考产品。

          医疗保健初创企业数量不断增加

          在过去的十年中,制药行业见证了许多变革趋势和创新,这些趋势和创新将迅速改善世界各地患者可获得的药物。在短短十年内,人工智能和大数据对疾病诊断和治疗的影响,以及从预防危及生命的疾病而不是药物治疗的转变,导致了医疗保健的发展。随着最新技术的发展,新进入者创办了多家健康初创企业,从而影响了中型制药市场。例如:Alpha Zyme 由开发和生产专家 Christopher Benoit 于 2018 年创立。 2020年10月,Alpzyme与Qualio合作,促进公司发展。

          中型制药市场报告细分分析

          有助于中型制药市场分析的关键部分是类型、药物开发类型、配方和治疗类别。

          • 根据类型,中型制药市场分为处方药和非处方药。 2023 年,场外交易市场占据了最重要的市场份额。
          • 根据药物开发类型,中型制药市场可分为内部和外包。 2023 年,外包细分市场占据最大市场份额。
          • 根据剂型,中型药品市场可分为片剂和胶囊、注射剂、喷雾剂和其他剂型。 2023 年,片剂和胶囊细分市场占据最大市场份额。
          • 根据治疗类别,中型制药市场按心血管疾病、疼痛管理、糖尿病、癌症和其他疾病进行细分。 2023 年,糖尿病细分市场占据最重要的市场份额。

          按地域划分的中型制药市场份额分析

          中型医药市场报告的地理范围主要分为五个地区:北美、亚太地区、欧洲、中东和非洲、南美洲和中美洲。

          美国是北美最大的中型药品市场。在北美,美国在中型制药市场中占有重要份额。该国市场的增长主要是由美国人口老龄化的加剧和慢性病患病率的上升推动的。美国人口老龄化的加剧可能有利于中型制药市场的增长。根据美国人口普查局的数据,美国 65 岁及以上人口预计将增加一倍,从 2018 年的 5200 万增加到 2060 年的 9500 万左右,而 2018 年 65 岁及以上人口将从 16% 增加到 23%到2060年。

          大多数成年人 (>60%) 患有两种或多种慢性病。根据美国疾病控制与预防中心 (CDC) 的数据,2020 年,美国近十分之六的人患有至少一种慢性病,十分之四的人患有两种或两种以上慢性病。此外,痴呆、心脏病、2型糖尿病、关节炎和癌症等慢性疾病都与衰老有关。这些是美国疾病、残疾、死亡和医疗费用增加的重要原因。

          中型医药市场报告范围

          报告属性细节
          2023年市场规模7320.2亿美元
          2031 年市场规模12,240.39 亿美元
          全球复合年增长率(2023 - 2031)8.9%
          历史数据2021-2022
          预测期2024-2031
          涵盖的细分市场按类型
          • 处方
          • 在柜台
          按药物开发类型
          • 内部和外包
          按配方分类
          • 片剂和胶囊
          • 注射剂
          • 喷雾剂
          • 其他配方
          按治疗类别
          • 心血管疾病
          • 疼痛管理
          • 糖尿病
          • 癌症
          • 其他条件
          覆盖地区和国家北美
          • 我们
          • 加拿大
          • 墨西哥
          欧洲
          • 英国
          • 德国
          • 法国
          • 俄罗斯
          • 意大利
          • 欧洲其他地区
          亚太
          • 中国
          • 印度
          • 日本
          • 澳大利亚
          • 亚太其他地区
          南美洲和中美洲
          • 巴西
          • 阿根廷
          • 南美洲和中美洲其他地区
          中东和非洲
          • 南非
          • 沙特阿拉伯
          • 阿联酋
          • 中东和非洲其他地区
          市场领导者和主要公司简介
          • 第一三共有限公司;
          • 卫材有限公司;
          • 再生元制药公司;
          • 博士健康公司;
          • 太阳制药工业有限公司;
          • 亚力兄制药公司;
          • 马林克罗特;
          • 远藤制药公司;
          • 施维雅实验室;
          • 联合银行有限公司
          • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

          中型制药市场新闻和最新动态

          中型制药市场是通过收集初级和二级研究后的定性和定量数据进行评估的,其中包括重要的公司出版物、协会数据和数据库。下面列出了中型制药市场的一些发展:

          • Regeneron Pharmaceuticals, Inc. 和 Checkmate Pharmaceuticals, Inc. 宣布达成最终协议,Regeneron 将通过全现金交易以每股 10.50 美元的 Checkmate 普通股收购 Checkmate。在拟议的收购中,Checkmate 的全部股票价值估计约为 2.5 亿美元。 (来源:Regeneron Pharmaceuticals, Inc,公司网站,2022 年 4 月)

          中型制药市场报告范围和交付成果

          《中型制药市场规模和预测(2021-2031)》报告对涵盖以下领域的市场进行了详细分析:

          • 中型制药市场规模以及全球、区域和国家层面涵盖的所有关键细分市场的预测
          • 中型制药市场趋势以及市场动态,例如驱动因素、限制因素和关键机遇
          • 详细的 PEST/波特五力分析和 SWOT 分析
          • 中型制药市场分析,涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展。
          • 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及中型制药市场的最新发展
          • 详细的公司简介

          Mid-Size Pharmaceutical Market Report Scope

          Report Attribute Details
          Market size in US$ 732.02 Billion
          Market Size by US$ 1,224.039 Billion
          Global CAGR 8.9%
          Historical Data 2021-2022
          Forecast period 2024-2031
          Segments Covered By 类型(处方药、非处方药)
          By 药物开发类型(内部和外包)
          By 剂型(药片、胶囊、注射剂、喷雾剂、其他剂型)
          By 治疗课程(心血管疾病、疼痛管理、糖尿病、癌症、其他疾病)
          Regions and Countries Covered 北美(美国、加拿大、墨西哥)
          • 北美(美国、加拿大、墨西哥)
          欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
          • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
          亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
          • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
          南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
          • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
          中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
          • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
          Market leaders and key company profiles
        • DAIICHI SANKYO COMPANY LIMITED
        • Eisai Co Ltd
        • Regeneron Pharmaceuticals Inc
        • Bausch Health Companies Inc
        • Sun Pharmaceutical Industries Ltd
        • Alexion Pharmaceuticals Inc
        • Mallinckrodt
        • Endo Pharmaceuticals Inc
        • Les Laboratories Servier
        • UCB S A
        • Report Coverage
          Report Coverage

          Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

          Segment Covered
          Segment Covered

          This text is related
          to segments covered.

          Regional Scope
          Regional Scope

          North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

          Country Scope
          Country Scope

          This text is related
          to country scope.

          Frequently Asked Questions


          Which region dominated the mid-size pharmaceutical market in 2023?

          North America dominated the mid-size pharmaceutical market in 2023

          What are the driving factors impacting the mid-size pharmaceutical market?

          The growth of the market is defined by key driving factors, such as the rising geriatric population across the globe, along with the increased prevalence of chronic disorders. Moreover, increased urbanization has increased government expenditures on the healthcare sector.

          What are the future trends of the mid-size pharmaceutical market?

          Greater focus on R&D will likely remain a key trend in the market.

          Which are the leading players operating in the mid-size pharmaceutical market?

          DAIICHI SANKYO COMPANY LIMITED; Eisai Co., Ltd.; Regeneron Pharmaceuticals, Inc; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd; Alexion Pharmaceuticals, Inc.; Mallinckrodt; Endo Pharmaceuticals Inc.; Les Laboratories Servier; and UCB S.A.

          What is the expected CAGR of the mid-size pharmaceutical market?

          The market is expected to register a CAGR of 8.9% during 2023–2031.

          The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

          1. Data Collection and Secondary Research:

          As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

          Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

          1. Primary Research:

          The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

          For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

          A typical research interview fulfils the following functions:

          • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
          • Validates and strengthens in-house secondary research findings
          • Develops the analysis team’s expertise and market understanding

          Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

          • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
          • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

          Below is the breakup of our primary respondents by company, designation, and region:

          Research Methodology

          Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

          1. Data Analysis:

          Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

          • Macro-Economic Factor Analysis:

          We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

          • Country Level Data:

          Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

          • Company Profile:

          The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

          • Developing Base Number:

          Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

          1. Data Triangulation and Final Review:

          The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

          We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

          We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

          Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

          Trends and growth analysis reports related to Pharmaceuticals : READ MORE..